Show Summary Details
Page of

Nanoformulated Medicines 

Nanoformulated Medicines
Chapter:
Nanoformulated Medicines
Author(s):

Upal Roy

, Shantanu Balkundi

, JoEllyn McMillan

, and Howard E. Gendelman

DOI:
10.1093/med/9780195399349.003.0070
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 May 2019

Nanomaterials are being exploited with the goals to improve antiretroviral therapeutic efficacy, pharmacokinetics, and patient compliance. Importantly such materials can also be used for bioimaging to improve disease diagnosis and therapeutic monitoring. The targeted objectives all together are to attenuate human immunodeficiency virus (HIV) infection and positively affect the outcomes of disease manifestations in the infected human host. We posit that antiretroviral therapy delivery can be enhanced by formulating or encapsulating drugs with surfactants. Such nanoformulated drugs are readily taken up by the reticuloendothelial system (RES), the natural target for HIV. Recent works have explored the development of cell-based delivery systems using macrophages as drug carriers. This scheme has been shown to enhance nervous system RES delivery as macrophages are actively phagocytic cells and readily cross tissue barriers. Another major advantage of using cells as drug carriers is the potential to deliver a broad range of medicines with different biochemical properties to disease sites. This chapter discusses the potentials and perils for nanoformulated drug developments, with a particular focus on antiretroviral agents.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.